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a b s t r a c t
Background: Monitoring influenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for
detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supple-
mented by NA sequence analysis. However, differences in NI testing methodologies between surveillance
laboratories results in variability of 50% inhibitory concentration (IC50) values, which impacts data
sharing, reporting and interpretation. In 2011, the Centers for Disease Control and Prevention (CDC), in
collaboration with the Association for Public Health Laboratories (APHL) spearheaded efforts to stan-
dardize fluorescence-based NI assay testing in the United States (U.S.), with the goal of achieving con-
sistency of IC50 data.
Methods: For the standardization process, three participating state public health laboratories (PHLs),
designated as National Surveillance Reference Centers for Influenza (NSRC-Is), assessed the NAI sus-
ceptibility of the 2011e12 CDC reference virus panel using stepwise procedures, with support from the
CDC reference laboratory. Next, the NSRC-Is assessed the NAI susceptibility of season 2011e12 U.S.
influenza surveillance isolates (n ¼ 940), with a large subset (n ¼ 742) tested in parallel by CDC. Sub-
sequently, U.S. influenza surveillance isolates (n ¼ 9629) circulating during the next three influenza
seasons (2012e15), were independently tested by the three NSRC-Is (n ¼ 7331) and CDC (n ¼ 2298).
Results: The NI assay IC50s generated by respective NSRC-Is using viruses and drugs prepared by CDC
were similar to those obtained with viruses and drugs prepared in-house, and were uniform between
laboratories. IC50s for U.S. surveillance isolates tested during four consecutive influenza seasons (2011
e15) were consistent from season to season, within and between laboratories.
Conclusion: These results show that the NI assay is robust enough to be standardized, marking the first
time IC50 data have been normalized across multiple laboratories, and used for U.S. national NAI sus-
ceptibility surveillance.
Published by Elsevier B.V.
1. Introduction
Neuraminidase (NA) inhibitors (NAIs) are currently the only
class of antiviral drugs recommended by Centers for Disease Con-
trol and Prevention (CDC) for the control of influenza infections,
due to widespread resistance to the M2 blockers (adamantanes)
* Corresponding author. Mail Stop G-16, 1600 Clifton Road, Atlanta, GA 30333,
USA.
E-mail address: lgubareva@cdc.gov (L.V. Gubareva).
1 Present affiliation: Division of Global HIV/AIDS, CGH, CDC, Atlanta, GA, USA.
2 Present affiliation: Battelle, Atlanta, GA, USA.
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier .com/locate /ant iv iral
http://dx.doi.org/10.1016/j.antiviral.2016.01.009
0166-3542/Published by Elsevier B.V.
Antiviral Research 128 (2016) 28e35
(Deyde et al., 2007). In 1999, orally administered oseltamivir and
inhaled zanamivir were approved by the United States (U.S.) Food
and Drug Administration (FDA) for control of influenza type A and B
infections. In December 2014, a third NAI, intravenous peramivir
(Shetty and Peek, 2012), was FDA-approved. Peramivir is also
licensed in Japan, South Korea and China, while inhaled laninamivir
(Yamashita et al., 2009) is approved in Japan. Intravenous zanamivir
has been provided for compassionate use in recent years, and is
undergoing evaluation for treatment of hospitalized patients with
severe influenza (https://clinicaltrials.gov/show/NCT01231620).
During initial post-marketing years, monitoring influenza virus
susceptibility to NAIs was carried out by a central laboratory con-
tracted by the Neuraminidase Inhibitor Susceptibility Network
(NISN) which utilized chemiluminescence- and fluorescence-based
NI assays (Wetherall et al., 2003). Later, monitoring NAI-
susceptibility became an integral part of virological surveillance
within the WHO Global Influenza Surveillance and Response Sys-
tem (WHO-GISRS), where both functional (NA inhibition) and
sequence-based (pyrosequencing, real time RT-PCR, Sanger) assays
have been utilized to conduct drug susceptibility monitoring
worldwide (Monto et al., 2006; Meijer et al., 2014). Following the
FDA's approval of zanamivir and oseltamivir, CDC implemented the
NI assay, first using a chemiluminescence-based (Mungall et al.,
2004), then a fluorescence-based methodology (Okomo-
Adhiambo et al., 2013). The NI assay testing is done for the pur-
pose of monitoring changes in the baseline NAI susceptibility of
circulating influenza viruses.
Historically, there has been significant variability in IC50 data
(the drug concentration required to inhibit 50% of viral NA enzyme
activity), due to factors such as variations in assay choice and/or
assay conditions. The lack of standardization in NI assay method-
ologies and the resulting IC50 variability has been a challenge in
sharing and interpreting IC50 data among laboratories. In 2012, in
efforts to harmonize the interpretation and reporting of IC50 data,
the WHO Expert Working Group for GISRS on Surveillance of
Antiviral Susceptibility (WHO-AVWG) agreed on criteria to define
influenza viruses as exhibiting normal, reduced (RI) or highly
reduced (HRI) NA inhibition, based on the fold change of their IC50
compared to reference IC50 values (WHO, 2012). These criteria have
been helpful in interpretation and reporting of NI assay data
generated by different WHO Collaborating Centers (Okomo-
Adhiambo et al., 2014; Takashita et al., 2014, 2015a), and for
providing annual global updates (Meijer et al., 2014; Takashita et al.,
2015b). Viruses of N1 subtype carrying the H275Y substitution in
the NA (H274Y in N2 subtype) and A(H3N2) viruses carrying E119V
or R292K substitutions consistently demonstrate HRI by oseltami-
vir in NI assays (Meijer et al., 2014; Okomo-Adhiambo et al., 2014;
Takashita et al., 2015b).
In the summer of 2011, the CDC spearheaded efforts to stan-
dardize influenza NI testing within the U.S., in collaboration with
the Association for Public Health Laboratories (APHL) and several
state public health laboratories (PHLs), with the goal of minimizing
NI assay IC50 data variability within and among surveillance labo-
ratories, as well as increasing the US capacity to monitor the NAI
susceptibility of influenza viruses. Three PHLs, designated as Na-
tional Surveillance Reference Centers for Influenza (NSRC-Is),
namely, the California Department of Public Health (CDPH), Rich-
mond, CA; Unified State Laboratories, Public Health (USLPH), Tay-
lorsville, UT; and the Wisconsin State Laboratory of Hygiene
(WSLH), Madison, WI, participated in the “Project for Standardi-
zation of NAI Susceptibility Testing,” through a step-wise procedure
developed by the CDC. In April 2012, Maryland Department of
Health and Mental Hygiene (MD DHMH) Laboratories Adminis-
tration also participated in an additional NI Standardization Project,
but was not selected as a NSRC-I.
After successfully completing the standardization process, the
three NSRC-Is performed NI assay testing on U.S. influenza sur-
veillance specimens collected during the 2011e12 season, and
three subsequent seasons, 2012e13, 2013e14, and 2014e15. The NI
assay testing activity was added to an ongoing APHL contract for
influenza virus isolation, collectively referred to as the “VI/NI
Project.” At CDC, standardized IC50 data generated by the NSRC-Is
were further analyzed based on criteria of the WHO-AVWG
(WHO, 2012) to identify viruses with RI or HRI, which were
genetically analyzed by pyrosequencing and/or conventional NA
sequence analysis to determine underlying NA changes responsible
for elevated IC50s. Viruses with markers previously associated with
resistance to NAI(s) were reported as NAI-resistant to the WHO
GISRS and in the U.S. influenza virological surveillance Report
(FluView) (http://www.cdc.gov/flu/weekly/).
This report describes results of the NI assay standardization
project performed on the 2011e12 CDC reference virus panel by
three NSRC-Is (CDPH, USLPH andWSLH), as well as NI assay data for
U.S. influenza surveillance isolates they tested during seasons
2011e15. These results suggest that NAI drug susceptibility data
generated in the NI assay can be interpreted and shared in a
consistent, reproducible manner when detailed procedures and
reference materials are used in assay implementation.
2. Materials and methods
2.1. Training
Prior to the standardization process, participating laboratories
received training on the fluorescent NI assay by CDC laboratorians,
through lectures and hands-on instruction. The training course,
conducted in April 2011, was sponsored by the APHL, CDC and
National Laboratory Training Network (NLTN), and comprised pre-
and post-test knowledge assessment; background information on
influenza and drug susceptibility testing; NI assay workflow; re-
agent and drug preparation; determination of virus dilutions for
use in the NI assay; identification of acceptable NI assay results;
equipment operation; IC50 data analysis and interpretation.
2.2. Viruses
The 2011e12 CDC reference panel (Table 1) comprising wildtype
and variant virus pairs of seasonal influenza types/subtypes, as well
as surveillance isolates circulating during the 2011e14 influenza
seasons were propagated in MadineDarby canine kidney (MDCK)
cells provided by CDC. Since October, 2014 (season 2014e15)
influenza A(H3N2) viruses are propagated in MDCK-SIAT1 cells,
also provided by CDC. Note, an updated CDC reference virus panel
version 2, for NAI susceptibility testing, was introduced in October,
2012 (season 2012e13), and comprises viruses different from those
in the 2011e2012 panel, with exception of A/Washington/01/
2007(H3N2) wildtype, A/Texas/12/2007(H3N2) NA-E119V, B/
Memphis/20/96 wildtype and B/Memphis/20/96 NA-R152K
(Supplementary Table S1). Laboratories conducting influenza
virological surveillance using NI assays can obtain this panel from
the Influenza Reagent Resource (IRR) upon registration and
approval (Catalogue No. FR-1176) (http://
www.influenzareagentresource.org/Catalog.aspx).
2.3. Neuraminidase inhibitors
Oseltamivir carboxylate, the active compound of the ethyl ester
prodrug oseltamivir phosphate was kindly provided by Hoffmann-
La Roche (Basel, Switzerland), zanamivir by GlaxoSmithKline
(Uxbridge, UK), and peramivir by BioCryst Pharmaceuticals
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(Birmingham, AL). Note, oseltamivir, zanamivir and peramivir are
also available commercially (Sequoia Research Products, Pan-
gbourne, United Kingdom). In this study, NAIs (in powder form)
were obtained from respective manufacturers through material
transfer agreements (MTAs), thenweighed and reconstituted using
deionized distilled water (to 20 mM solutions), according to pro-
cedures described in the CDC fluorescent NI assay protocol. These
20 mM solutions were then diluted into 50 mM stock solutions,
which were used to prepare 3.16-fold (half-log10) serial dilutions of
NAIs (total of 10), starting from 4 mM (4000 nM) to a final con-
centration of 0.12 nM.
2.4. Neuraminidase inhibition assay
Virus susceptibility to NAIs was assessed in the fluorescent NI
assay that utilizes 2-(4-methylumbelliferyl)-a-D-N-acetylneur-
aminic acid (MUNANA) as substrate. The assay was performed us-
ing the NA-Fluor™ Influenza Neuraminidase Assay Kit (Applied
Biosystems/Life Technologies, Carlsbad, CA) in 96-well opaque
black flat-bottom microplates (Corning Inc., Corning, NY), accord-
ing to the CDC protocol, which can be requested by email
(fluantiviral@cdc.gov). The CDC fluorescent NI assay protocol is
optimized to the needs of virological surveillance (Okomo-
Adhiambo et al., 2013) and somewhat differs from the manufac-
turer's instructions in the NA-Fluor™ kit manual. Briefly, viruses
were diluted at concentrations corresponding to the target fluo-
rescence signal generated by 1000 pmol/well of 4-
methylumbelliferone (4-MU) standard. A virus dilution calcula-
tion spreadsheet (Excel, Microsoft, Redmond, WA) was used to
determine the appropriate dilution of virus to be used in the in-
hibition portion of the assay. This tool rapidly provides the dilutions
of virus, together with the volumes of virus and 1 NA-Fluor™
Assay Buffer to be used. Subsequently, 25 mL of each diluted virus
was mixed with 25 mL of a range of concentrations of each NAI
(0.12 nMe4000 nM; with a final concentration in the reaction of
0.03 nMe1000 nM) and incubated at 37 C for 45 min, after which
50 mL of the 200 mMNA-Fluor™ Substrate (MUNANA) was added to
the virus and inhibitor mix, and incubated at 37 C for 60 min. The
reaction was terminated with 100 mL NA-Fluor™ Stop Solution.
Fluorescence was detected on the Victor3 V™ (USLPH), Victor X4™
(WSLH) or Victor X2™ (CDPH) plate reader (PerkinElmer, Shelton,
CT), equipped with filters for excitation (l ¼ 365 nm) and emission
(l ¼ 450 nm). Note, the CDC currently uses the BioTek™ plate
reader platform,models Synergy H1™, Synergy Neo™ and Cytation
3™ (BioTek Instruments Inc., Winooski, VT).
2.5. Resources provided by CDC
Participating laboratories (NSRC-Is) were provided with a
detailed standard operating procedure (SOP) for the fluorescent NI
assay utilizing the NA-Fluor™ Influenza Neuraminidase Assay Kit
(Okomo-Adhiambo et al., 2013). Besides the SOP, the CDC also
provided materials and tools, including a virus dilution calculator
tool; JASPR v1.2 curve-fitting software (CDC, Atlanta, GA); the
2011e12 CDC reference virus panel; aliquots of verified 50 mM NAI
stock solutions (for the first phase of the study); and technical
support for troubleshooting. Additionally, CDC laboratorians con-
ducted site visits to monitor NI assay implementation for the
impending 2011e12 influenza season.
2.6. Testing algorithm for NI assay standardization
In the first phase of the standardization process, participating
laboratories (NSRC-Is) performed the NI assay on 2011e12 CDC
reference panel viruses grown by CDC (n ¼ 8), using NAIs that the
CDC obtained, weighed, reconstituted and diluted. The laboratories
were provided with 50 mM NAI stock solutions which they diluted
to the final concentrations (0.12e4000 nM) required for NI assay
testing. For the second phase, participating laboratories prepared
their own stocks of the 2011e12 CDC reference panel viruses, and
tested them with NAIs they obtained from manufacturers in pow-
der form, and weighed, reconstituted and diluted in-house.
Commonly, each NI assay test was replicated at least twice. After
successfully completing the NI assay standardization process, the
NSRC-Is tested U.S. influenza A and B surveillance isolates collected
during the 2011e12 season (n ¼ 940), using NAIs obtained and
prepared in-house. A subset (n ¼ 742) of these viruses were tested
in parallel by the CDC. The 2011e12 CDC reference panel influenza
A(H1N1)pdm09 viruses, A/California/07/2009 wildtype and A/
North Carolina/39/2009 H257Y, were included in each NI assay test
as controls. Note, the tested surveillance isolates were propagated
by NSRC-Is as part of the VI/NI project or by CDC (viruses submitted
to CDC directly), and NAIs were prepared by each NSRC-I and the
CDC, respectively. Subsequently, the NSRC-Is tested surveillance
isolates (n ¼ 6773) circulating during the 2012e15 influenza sea-
sons; the A(H1N1)pdm09 viruses, A/California/12/2012 wildtype
and A/Texas/23/2012 H275Y, from CDC reference virus panel
version 2, were included in each NI assay test for quality control. All
NI assay data generated by the NSRC-Is were submitted to the CDC
for evaluation via secure file transfer protocol (FTP).
2.7. Data analysis
Fifty percent inhibitory concentration (IC50) values were deter-
mined using JASPR v1.2 curve-fitting software (CDC, Atlanta, GA) by
participating laboratories. The CDC laboratory performed statistical
analyses of IC50 values using SAS v9.3 (SAS Institute, Cary, NC), with
statistical significance set at a ¼ 0.05. One-way analysis of variance
Table 1
Fluorescent NI assay IC50s for the 2011e12 CDC reference virus panel, tested by CDC.
Virus name Influenza type/subtype Mean IC50 ± SDa [Range]b (nM)
Oseltamivir Zanamivir Peramivir
A/California/07/2009 Wildtype A(H1N1)pdm09 0.21 ± 0.02 [0.19e0.23] 0.20 ± 0.01 [0.19e0.21] 0.05 ± 0.05 [0.05e0.05]
A/North Carolina/39/2009 H275Y A(H1N1)pdm09 151.13 ± 12.08 [140.04e164.00] 0.22 ± 0.01 [0.21e0.22] 17.75 ± 0.66 [17.03e18.33]
A/Washington/10/2008 Wildtype A(H1N1) 0.59 ± 0.08 [0.50e0.65] 0.25 ± 0.05 [0.21e0.30] 0.07 ± 0.01 [0.06e0.08]
A/Florida/21/2008 H275Y A(H1N1) 562.97 ± 55.49 [504.00e614.15] 0.52 ± 0.08 [0.43e0.58] 73.48 ± 10.61 [61.63e82.11]
A/Washington/01/2007 Wildtype A(H3N2) 0.06 ± 0.01 [0.05e0.07] 0.69 ± 0.14 [0.55e0.82] 0.08 ± 0.01 [0.07e0.09]
A/Texas/12/2007 E119V A(H3N2) 45.36 ± 7.30 [40.42e53.75] 0.46 ± 0.05 [0.43e0.51] 0.10 ± 0.09 [0.09e0.11]
B/Memphis/20/1996 Wildtype B 4.45 ± 0.19 [4.28e4.65] 1.19 ± 0.04 [1.16e1.24] 0.30 ± 0.02 [0.29e0.32]
B/Memphis/20/1996 R152K B 600.38 ± 84.81 [523.81e690.89] 62.60 ± 5.18 [56.87e66.96] 278.22 ± 21.16 [254.17e293.99]
Abbreviations - SD: Standard deviation.
a Three independent NI assays.
b Range: minimum to maximum IC50.
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(ANOVA) was used to compare means of IC50s generated for the
2011e12 reference virus panel tested for the standardization pro-
cess, while non-parametric ANOVA (Pappas and DePuy, 2004) was
used to compare medians of IC50s for the 2011e15 U.S. surveillance
isolates.
2.8. Sequence analysis
To identify known and/or novel markers associated with
elevated IC50, viral RNA was extracted from isolates and NA
sequence analyzed by pyrosequencing (Deyde and Gubareva, 2009)
and/or Sanger sequencing (Sheu et al., 2008). Amino acid sub-
stitutions are named according to specific influenza A NA subtype
or B type sequence numbering (straight numbering).
3. Results
The NI assay standardization process was conducted on the
2011e12 CDC reference virus panel (Table 1) comprising four pairs
of wildtype virus and NA variants with known molecular markers
previously associated with elevated IC50s for one or more NAIs,
covering a wide range of IC50 values. The three participating labo-
ratories designated as NSRC-Is (CDPH, USLPH, and WSLH), first
tested the 2011e12 CDC reference virus panel propagated by CDC,
using NAIs obtained and prepared by the CDC (the laboratories
were provided with 50 mM stock solutions which they diluted
further). This was followed by testing of the same reference virus
panel propagated by each participating laboratory, and using NAIs
they obtained and prepared in-house (Table 2).
The IC50s generated for CDC-propagated viruses with CDC-
prepared NAIs (Table 2) were similar and exhibited minimal
inter-assay variation within respective laboratories. There was
minimal inter-laboratory variation in IC50s, which, with few ex-
ceptions, was statistically insignificant. For example, the zanamivir
IC50 for A/Washington/10/2008(H1N1) wildtype virus generated by
WSLH (0.32 nM) was 2-fold greater than that for CDPH (0.16 nM),
while zanamivir IC50 for B/Memphis/20/1996 R152K variant virus
generated by CDPH (67.94 nM) was 2-fold more than for USLPH
(33.13 nM) and WSLH (43.20 nM). Similarly, the peramivir IC50 for
A/Washington/01/2007(H3N2) wildtype virus generated by WSLH
(0.14 nM) was 2-3-fold higher compared to those of CDPH
(0.06 nM) and USLPH (0.05 nM). These differences were not sta-
tistically significant (p > 0.05).
Using viruses they propagated and NAIs prepared in-house, the
participating laboratories were able to successfully reproduce the
IC50s they generated using the viruses and NAIs prepared by the
CDC (p-values comparing IC50s derived from the two scenarios
were insignificant, range 0.073e0.980). These IC50s also exhibited
minimal inter-assay and inter-laboratory variation, although those
generated by USLPH tended to be lower (2-fold) compared to
those of CDPH and WSLH. However, these differences were
generally <2-fold and were not significant at the assessed level of
confidence (p > 0.05). Overall, the IC50s for the 2011e12 reference
virus panel generated by the three laboratories for the standardi-
zation process, were comparable to those generated by the CDC for
the same reference virus panel (Table 1), and were within the
ranges expected for wildtype and NA variant virus pairs of the four
influenza type/subtypes that were assessed.
Upon completion of testing the 2011e12 CDC reference virus
panel for the standardization process, and implementing the NI
Table 2
Fluorescent NI assay IC50s for the 2011e12 CDC reference virus panel, tested by three NSRC-Is (CDPH, USLPH and WSLH) for the standardization process.
NAI Virus name Influenza type/Subtype Mean IC50 ± SD (nM)
CDC Drug/Virusa,y PHL Drug/Virusb,y
CDPH USLPH WSLH CDPHc USLPH WSLH
Oseltamivir A/California/07/2009 Wildtype A(H1N1)pdm09 0.15 ± 0.06 0.16 ± 0.11 0.11 ± 0.02 0.09 0.12 ± 0.03 0.18 ± 0.06
A/North Carolina/39/2009 H275Y A(H1N1)pdm09 140.44 ± 15.58 120.58 ± 36.71 135.39 ± 15.85 128.76 117.02 ± 21.62 146.64 ± 16.7
A/Washington/10/2008 Wildtype A(H1N1) 0.38 ± 0.08 0.42 ± 0.27 0.34 ± 0.06 0.36 0.33 ± 0.08 0.96 ± 0.97
A/Florida/21/2008 H275Y A(H1N1) 431.27 ± 44.64 319.71 ± 124.5 404.18 ± 19.11 399.73 234.54 ± 33.06 452.63 ± 79.77
A/Washington/01/2007 Wildtype A(H3N2) 0.05 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 0.04 0.04 ± 0.00 0.04 ± 0.01
A/Texas/12/2007 E119V A(H3N2) 34.21 ± 0.62 33.53 ± 12.75 28.48 ± 5.23 33.01 27.45 ± 6.26 39.76 ± 17.68
B/Memphis/20/1996 Wildtype B 3.88 ± 1.03 3.11 ± 1.93 2.72 ± 0.56 2.46 2.40 ± 0.51 3.30 ± 1.79
B/Memphis/20/1996 R152K B 472.84 ± 47.23 421.62 ± 120.11 410.49 ± 48.62 469.35 311.30 ± 37.50 473.88 ± 37.41
Zanamivir A/California/07/2009 Wildtype A(H1N1)pdm09 0.15 ± 0.02 0.16 ± 0.05 0.14 ± 0.03 0.13 0.16 ± 0.03 ed
A/North Carolina/39/2009 H275Y A(H1N1)pdm09 0.14 ± 0.01 0.17 ± 0.06 0.16 ± 0.03 0.12 0.20 ± 0.01 e
A/Washington/10/2008 Wildtype A(H1N1) 0.16 ± 0.01 0.23 ± 0.09 0.32 ± 0.12 0.17 0.23 ± 0.01 e
A/Florida/21/2008 H275Y A(H1N1) 0.52 ± 0.09 0.61 ± 0.37 0.76 ± 0.21 0.45 0.54 ± 0.06 e
A/Washington/01/2007 Wildtype A(H3N2) 0.76 ± 0.35 0.75 ± 0.48 0.60 ± 0.26 0.52 0.93 ± 0.47 e
A/Texas/12/2007 E119V A(H3N2) 0.26 ± 0.08 0.35 ± 0.12 0.34 ± 0.07 0.25 0.38 ± 0.01 e
B/Memphis/20/1996 Wildtype B 0.71 ± 0.21 0.81 ± 0.35 0.74 ± 0.09 0.59 0.76 ± 0.09 e
B/Memphis/20/1996 R152K B 67.94 ± 2.20 33.13 ± 24.59 43.20 ± 12.21 49.90 23.73 ± 4.45 e
Peramivir A/California/07/2009 Wildtype A(H1N1)pdm09 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01 0.04 0.05 ± 0.01 0.02 ± 0.01
A/North Carolina/39/2009 H275Y A(H1N1)pdm09 14.97 ± 0.40 15.63 ± 3.94 13.98 ± 2.66 18.97 17.45 ± 1.89 14.45 ± 1.4
A/Washington/10/2008 Wildtype A(H1N1) 0.04 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.05 0.07 ± 0.02 0.06 ± 0.03
A/Florida/21/2008 H275Y A(H1N1) 65.60 ± 0.00 67.89 ± 11.48 64.32 ± 11.59 71.17 68.14 ± 6.59 67.61 ± 14.61
A/Washington/01/2007 Wildtype A(H3N2) 0.06 ± 0.01 0.05 ± 0.02 0.14 ± 0.10 0.06 0.07 ± 0.02 0.05 ± 0.01
A/Texas/12/2007 E119V A(H3N2) 0.08 ± 0.02 0.08 ± 0.02 0.06 ± 0.02 0.09 0.10 ± 0.03 0.06 ± 0.02
B/Memphis/20/1996 Wildtype B 0.23 ± 0.09 0.24 ± 0.06 0.20 ± 0.04 0.26 0.35 ± 0.13 0.18 ± 0.02
B/Memphis/20/1996 R152K B 256.27 ± 32.63 215.92 ± 35.38 208.57 ± 52.42 245.65 229.11 ± 43.03 244.9 ± 78.28
Abbreviations e PHL: state public health laboratory; CDPH: California Department of Public Health; USLPH: Utah Unified State Laboratories-Public Health; WSLH: Wisconsin
State Laboratory of Hygiene. SD: standard deviation.
yANOVA p-values (a ¼ 0.05) comparing IC50 means generated using CDC virus/drug vs PHL virus/drug, for each respective PHL and virus, were all insignificant (range of p-
values 0.073e0.980).
a CDC-propagated virus tested with CDC-reconstituted drug (PHLs diluted provided 50 mM solutions). Assay replicated twice.
b PHL-propagated virus tested with PHL-reconstituted/diluted drug. Assay replicated twice, with exceptions.
c Assay performed only once.
d Zanamivir not available for testing.
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assay, the three NSRC-Is (CDPH, USLPH and WSLH) performed the
NI assay on 2011e12 U.S. influenza surveillance specimens
(Table 3), in efforts to strengthen domestic influenza virological
surveillance. A total of 940 virus isolates were tested by the NSRC-
Is, of which 742 (80%) were tested in parallel by CDC for data quality
purposes, and to enable testing of virus susceptibility to investi-
gational laninamivir (data not shown). Within individual labora-
tories, there was minimal inter-assay variation in IC50s for the
respective NAIs and virus type/subtypes (Table 3). Inter-laboratory
variation in IC50s was also minimal, with few exceptions that were
not statistically significant (p > 0.05). For example, the mean
oseltamivir IC50 for A(H1N1)pdm09 viruses generated by WSLH
(0.12 nM) was ~2-fold lower than that for CDPH (0.19 nM) and only
slightly less than for USLPH (0.16 nM). Similarly, the mean per-
amivir IC50 for B viruses generated by WSLH (0.27 nM) was ~2-fold
lower than those for CDPH (0.49 nM) and USLPH (0.54 nM). Overall,
the IC50s for respective NAIs and virus type/subtypes generated by
the NSRC-Is, were consistent and comparable with those generated
by the CDC for the same set of viruses (Table 3).
As outlined in the CDC SOP for the fluorescent NI assay, the pair
of A(H1N1)pdm09 viruses, A/California/07/2009 wildtype and A/
North Carolina/39/2009 NA-H275Y, from the 2011e12 CDC refer-
ence panel, were propagated by NSRC-Is to prepare sizeable stocks
to enable aliquots of these viruses to be included in each NI assay
test for quality control purposes. Note, in October 2012, these vi-
ruses were replaced by the A(H1N1)pdm09 virus pair, A/California/
12/2012 wildtype and A/Texas/23/2012 H275Y, that are in the
current CDC reference virus panel version 2.
Following successful NI assay testing in season 2011e12, the
three NSRC-Is continued testing U.S. surveillance isolates
(n ¼ 6773) circulating during the 2012e13 (n ¼ 2114), 2013e14
(n¼ 2756) and 2014e15 (n¼ 1903) influenza seasons. During these
three seasons, as well as the previous 2011e12 season, the NSRC-Is
assessed virus susceptibility to three NAIs, oseltamivir, zanamivir
and peramivir, but in 2012e13 they did not monitor peramivir
susceptibility. Median IC50s for oseltamivir, zanamivir and per-
amivir generated by the NSRC-Is during four influenza seasons
(2011e15) were generally uniform within individual laboratories
from season to season (Fig. 1), although a few exceptions were
noted. Within WSLH, the median IC50 for peramivir among influ-
enza A(H1N1)pdm09 viruses in 2011e12 (0.03 nM) was ~2-fold
lower compared to seasons 2013e14 (0.05 nM) and 2014e15
(0.06 nM). Among the NSRC-Is, median IC50s for respective NAIs
and virus type/subtypes were consistent during 2011e2015, with
few exceptions, such as the 2014e15 median IC50 of oseltamivir
among influenza B generated by CDPH (10.54 nM), which varied by
almost 2-fold compared to USLPH (4.99 nM) and was slightly
higher than that for WSLH (7.15 nM). Overall, the median IC50s
obtained by the NSRC-Is over four seasons (2011e15), for respective
NAIs and virus type/subtypes, were consistent with those gener-
ated by CDC (Supplemental Table S2), and differences if any were
2-fold and not statistically significant (p < 0.05).
The standardization process significantly increased capabilities
for the NI assay in the U.S., with NSRC-Is accounting for ~80% of all
NI testing performed on U.S. surveillance isolates circulating during
the 2012e13, 2013e14 and 2014e15 influenza seasons. Standard-
izing the NI assay is, however, not practical for laboratories involved
in monitoring influenza antiviral susceptibility globally. To address
this issue, WHO-AVWG developed a set of criteria for reporting NI
assay results based on IC50 fold change difference compared to a
reference such as the median IC50 for the respective NAI and virus
type (WHO, 2012). During seasons 2012e15, these criteria were
applied to identify viruses with fold differences above a respective
median IC50 value for the same NAI and type/subtype; viruses
exhibiting RI or HRI were re-tested in the NI assay by NSRC-Is for
the result confirmation and submitted to CDC for comprehensive
characterization. In some instances, epidemiological investigations
were initiated by the CDC (Okomo-Adhiambo et al., 2015; Garg
et al., 2013).
The introduction of the WHO-AVWG criteria (WHO, 2012)
allowed an expanded scope of the original project. Two state PHLs
that were not part of the primary CDC/APHL standardization proj-
ect, MD DHMH, and the New York State Department of Health
(NYDOH), also conducted NI testing using the NA-Fluor™ Influenza
Neuraminidase Assay Kit, according to their in-house protocols. The
generated IC50 values were interpreted in accord with the WHO-
AVWG classification criteria. During the 2014e15 season, the MD
DHMH laboratory tested a total of 329 influenza A(H3N2) (n¼ 253)
and B (n ¼ 76) viruses collected in the state of Maryland between
Oct 01, 2014 and May 17, 2015. All viruses exhibited normal inhi-
bition by oseltamivir, zanamivir and peramivir, with exception of
one (0.4%) A(H3N2) virus with RI by zanamivir (15-fold increase in
IC50 compared to themedian IC50 for the subtype). This virus and its
original clinical specimen were submitted to CDC for further
Table 3
Fluorescent NI assay IC50s for season 2011e12 U.S. influenza A and B surveillance isolates, tested in parallel by the NSRC-Is and CDC (n ¼ 742).
NAI Influenza type/Subtype Mean IC50 ± SD [Range]a (nM) rf
CDPH (n ¼ 251) USLPH (n ¼ 248) WSLH (n ¼ 243) CDC (n ¼ 742)
Oseltamivir A(H1N1)pdm09 0.19 ± 0.06 [0.06e0.38]b 0.16 ± 0.04 [0.10e0.27]c 0.12 ± 0.02 [0.07e0.15]d 0.20 ± 0.05 [0.11e0.49]b,c,d 0.978
A(H3N2) 0.10 ± 0.04 [0.02e0.40] 0.11 ± 0.02 [0.07e0.20] 0.07 ± 0.03 [0.04e0.26] 0.12 ± 0.05 [0.04e0.53] 0.714
Bh 8.04 ± 2.42 [0.68e12.77]e 7.57 ± 2.04 [4.91e14.49] 5.45 ± 1.97 [0.10e14.00] 8.09 ± 2.92 [0.11e16.19]e 0.836
Zanamivir A(H1N1)pdm09 0.11 ± 0.02 [0.08e0.18]b 0.16 ± 0.03 [0.10e0.35] c eg 0.18 ± 0.04 [0.12e0.37]b,c,d 0.477
A(H3N2) 0.18 ± 0.09 [0.09e0.64] 0.24 ± 0.05 [0.13e0.40] e 0.28 ± 0.11 [0.12e0.98] 0.491
Bh 0.79 ± 0.29 [0.30e1.25] 1.11 ± 0.31 [0.67e1.70] e 1.29 ± 0.59 [0.49e2.38]e 0.572
Peramivir A(H1N1)pdm09 0.05 ± 0.01 [0.03e15.47]b 0.06 ± 0.01 [0.04e0.09]c 0.03 ± 0.01 [0.02e0.08]d 0.05 ± 0.01 [0.03e0.11]b,c,d 0.989
A(H3N2) 0.07 ± 0.01 [0.04e0.13] 0.09 ± 0.02 [0.06e0.16] 0.06 ± 0.02 [0.04e0.25] 0.09 ± 0.02 [0.04e0.35] 0.265
Bh 0.49 ± 0.21 [0.24e1.48]e 0.54 ± 0.12 [0.32e0.90] 0.27 ± 0.07 [0.07e0.54] 0.42 ± 0.15 [0.08e1.10]e 0.786
Abbreviations - CDPH: California Department of Public Health; USLPH: Utah Unified State Laboratories-Public Health; WSLH: Wisconsin State Laboratory of Hygiene. SD:
standard deviation.
a Range: minimum to maximum IC50.
b Excludes A/Texas/24/2012 H275Y variant (Ose ¼ 122.88 nM; Zan ¼ 0.12 nM; Per ¼ 15.47 nM).
c Excludes A/Illinois/01/2012 H275Y variant (Ose ¼ 132.67 nM; Zan ¼ 0.21 nM; Per ¼ 17.80 nM).
d Excludes A/Delaware/03/2012 H275Y variant (Ose ¼ 35.71 nM; Per ¼ 3.18 nM).
e Excludes B/California/03/2012 A200 A/T variant (Ose IC50 ¼ 30.39 nM; Zan IC50 ¼ 2.11 nM; Per IC50 ¼ 2.39).
f Pearson correlation coefficient between IC50s generated by PHLs and CDC for the same viruses.
g Zanamivir was not available for testing.
h There were no significant differences in IC50s between type B virus lineages.
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characterization. Full NA sequence analysis of the virus isolate
detected the cell culture adaptive Q136K substitution, which was
absent in the matching clinical specimen. The NYDOH laboratory
tested a total of 95 influenza A(H3N2) (n ¼ 78) and B (n ¼ 17) vi-
ruses collected in New York state between Jan 16 andMay 01, 2015;
all viruses exhibited normal inhibition by oseltamivir and zana-
mivir (peramivir was not assessed).
Overall, standardized NI assay procedure with three FDA-
approved NAIs, conducted by four laboratories (CDC and three
NSRC-Is) (n ¼ 3015), as well as harmonization of reporting from
two additional laboratories (MD DHMH and NYDOH) (n ¼ 424),
resulted in a total of 3439 circulating U.S. influenza viruses tested
during the 2014e15 season (Oct 01, 2014 to Jun 23, 2015), including
68 A(H1N1)pdm09, 2174 A(H3N2) and 1197 B viruses. Only two
(0.1%) U.S. viruses with molecular markers of NAI resistance were
detected, including one A(H1N1)pdm09 virus with H275Y and one
A(H3N2) virus with E119V NA substitutions.
4. Discussion
Biochemical NI assays have been the cornerstone of NAI sus-
ceptibility monitoring programs. They provide a valuable means to
screen virus isolates to identify those with elevated IC50s which can
indicate potential NAI resistance. Coupledwith genetic analysis, the
NI assay is especially valuable when information on drug resistance
markers is not available or sparse, such as when a new NAI is
marketed or a novel virus emerges (Sleeman et al., 2013, 2014). The
IC50 values generated in NI assays also provide information for
comparison of inhibitory effects of different NAIs thus aiding in
identification of cross-resistant viruses. Variations in IC50 values
determined for the same virus and drug can arise from sources such
as use of different enzyme substrates (fluorescent vs chemilumi-
nescent), buffer systems, time of incubation, and other assay con-
ditions (Nguyen et al., 2010; McKimm-Breschkin et al., 2003;
McKimm-Breschkin and Barrett, 2014; Tisdale, 2000).
Fig. 1. Median IC50s of oseltamivir, zanamivir and peramivir obtained by the three NSRC-Is (CDPH, USLPH and WSLH) for U.S. influenza A and B surveillance isolates circulating
during the influenza seasons of 2011e12 (n ¼ 940), 2012e13 (n ¼ 2114), 2013e14 (n ¼ 2757) and 2014e2015 (n ¼ 2640). Note, peramivir was not assessed by the three NSRC-Is in
season 2012e13.
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The goal of the standardization process was to achieve consis-
tency of IC50 data across participating laboratories through the
application of uniform NI assay testing procedures (same kit and
assay protocol) with support from the CDC reference laboratory. In
this study, critical factors including the use of a standardized SOP,
commercial NI assay kit, and the CDC reference virus panel, enabled
the generation of reproducible results among laboratories partici-
pating in the NI assay standardization process. Although partici-
pating laboratories and the CDC reference laboratory utilized
different plate reader models, all were equipped with standard
filters for excitation (l¼ 365 nm) and emission (l¼ 450 nm), set to
measure fluorescence for 0.1 s. All plate readers were calibrated
prior to their initial use by running 4-methylumbelliferone (4-MU)
standards to verify optimal plate reader settings and to determine
fluorescent signal targeted for virus working dilution. Viruses were
diluted at concentrations corresponding to the target fluorescence
signal generated by 1000 pmol/well of 4-methylumbelliferone (4-
MU) standard. This procedure was repeated whenever major
repair or recalibration was done to a plate reader. There were no
apparent variations in IC50s attributable to differences in plate
reader models.
The commercially available NA-Fluor™ Influenza Neuramini-
dase Assay Kit used in this study provides the necessary assay re-
agents, but it lacks NAIs and plates. It also does not include
reference material such as influenza viruses exhibiting a range of
IC50 values. Preparation of NAI and virus dilutions may vary by
laboratory, potentially resulting in IC50 variability. CDC provided
the NAI preparations to see if there were any differences in IC50s for
the viruses tested using CDC-prepared drug compared to testing
done with NAIs prepared in-house. Preparation of NAIs from their
original powder form to concentrations required for the NI assay
involves several steps, in which errors may be introduced. In this
study, the Tocris Molarity Calculator (http://www.tocris.com/
molarityCalculator.php) was used to determine appropriate vol-
umes of water for initial reconstitution of drugs from powder form.
Caution was taken during pipetting to ensure accurate volumes of
water were dispensed when diluting NAIs. Laboratories partici-
pating in the standardization project were advised to test newly
prepared NAIs in parallel to old drug preparations, to confirm ac-
curacy in reconstitution and dilution, and ensure consistency.
Although beyond the scope of this study, surveillance laboratories
could explore the option of requesting analytically pre-weighed
NAIs upon placing a purchase order to commercial entities that
offer zanamivir, oseltamivir carboxylate, and peramivir.
In this study, there was no evidence of IC50 variability arising
from drug preparation or viruses; differences in IC50s derived using
CDC- versus PHL-prepared drug were minimal (<2-fold) within
individual laboratories and also between the laboratories. Two-fold
differences in IC50s have been observed among personnel in the
same laboratory. The present study also showed no significant
variations in IC50s arising from virus propagation. Nevertheless,
participating laboratories were advised by the CDC to limit the
number of virus passages since it could lead to emergence of NA
changes resulting in elevated IC50s (Tamura et al., 2013; Mishin
et al., 2014).
The success of the NI assay standardization project affirmed that
NAI susceptibility data generated in the NI assay could be shared
and interpreted in a consistent, reproducible manner. The success
of this project can be attributed to several factors including good
laboratory practices; the participating laboratories have standard
practices of annual pipette calibration, as well as maintenance and
performance monitoring of equipment, including plate readers and
incubators. The set of tools developed by CDC and shared with the
three NSRC-Is, including the fluorescent NI assay SOP, virus dilution
calculator, software for IC50 calculation, seeds to propagate in-
house reference virus stocks, as well as other support and guid-
ance, were essential for the success of this project. Hands-on
training of personnel new to NI testing is also desirable, as is
maintaining optimized protocols, as well as necessary reagents,
reference viruses and NAI drug stocks. To sustain the quality of
future NI assay testing, prior to each upcoming influenza season,
laboratories should test reference panels such as CDC or ISIRV-AVG
(http://www.isirv.org/site/index.php/reference-panel). Ideally, ele-
ments of the NI assay including laboratory infrastructure, protocols,
technology, and reagents should be standardized in laboratories in
the U.S. and across the globe. However, many laboratories, espe-
cially those in resource-poor countries, lack the infrastructure and
means necessary to develop, validate, and comply with re-
quirements for NI assay standardization.
The successful implementation of NI testing on season 2011e12
surveillance isolates, and subsequent testing of viruses collected
during seasons 2012e15 by the NSRC-Is, proved the effectiveness of
the NI assay standardization and expansion efforts which spanned
5 years, and was instrumental in increasing U.S. domestic influenza
antiviral surveillance capabilities and pandemic preparedness. This
project marks the first time that IC50 data have been standardized
across multiple laboratories performing influenza antiviral sus-
ceptibility testing, and incorporated into the U.S. national virolog-
ical surveillance. The successful NI assay standardization process
will enable the expansion of the number of surveillance labora-
tories capable of drug susceptibility testing both nationally and
internationally, assessment of virus susceptibility to new NAIs and
testing of novel viruses. These efforts are expected to significantly
impact monitoring of influenza antiviral resistance, and will ensure
accurate, timely information for public health surveillance.
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SUPPLEMENTAL TABLES 
Supplemental Table S1. Fluorescent NI assay IC50 values for CDC Neuraminidase Inhibitor 
Susceptibility Reference Virus Panel version 2.0a 
Virus Name 
Influenza 
Type/Subtype 
IC50 (nM) 
Mean ± SD (Fold Change)b 
Oseltamivir Zanamivir 
A/California/12/2012 Wildtype A(H1N1)pdm09 0.20 ± 0.07 (1) 0.13 ± 0.06 (1) 
A/Texas/23/2012 H275Y A(H1N1)pdm09 174.91 ± 18.58 (875) 0.17 ± 0.02 (1) 
A/Washington/01/2007 
Wildtype 
A(H3N2) 0.08 ± 0.01 (1) 0.96 ± 0.25 (1) 
A/Texas/12/2007 E119V A(H3N2) 44.72 ± 7.15 (559) 0.37 ± 0.02 (1) 
B/Rochester/02/2001 Wildtype B 7.34 ± 0.98 (1) 0.74 ± 0.06 (1) 
B/Rochester/02/2001 D198N B 38.44 ± 4.48 (5) 5.54 ± 0.83 (7) 
B/Memphis/20/96 Wildtype B 4.25 ± 1.51 (1) 1.01 ± 0.09 (1) 
B/Memphis/20/96 R152K B 646.17 ± 90.32 (152) 46.60 ± 8.39 (46) 
Abbreviations - SD: Standard deviation 
a Source: CDC Neuraminidase Inhibitor Susceptibility Reference Virus Panel (version 2.0) - Product Information 
Sheet and Instructions for Use. 
b Fold difference in IC50 determined by dividing the IC50 for the type/subtype-specific variant virus by that of the 
corresponding wildtype matching virus. 
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Supplemental Table S2. Median fluorescent NI assay IC50s of oseltamivir, zanamivir and peramivir obtained by the three NSRC-
Is (CDPH, USLPH and WSLH) and the CDC for U.S. influenza A and B surveillance isolates circulating during the 2011-15 
influenza seasons 
NAI 
Influenza Type/ 
Subtype 
Median IC50 (nM), by influenza season 
2011-12 (n=2767)a 2012-13 (n=2915)b 2013-14 (n=3681)c 2014-15 (n=3033)d 
CDPH USLPH WSLH CDC CDPH USLPH WSLH CDC CDPH USLPH WSLH CDC CDPH USLPH WSLH CDC 
Oseltamivir 
A(H1N1)pdm09 0.17 0.16 0.12 0.19 0.21 0.14 0.10 0.17 0.16 0.19 0.13 0.20 0.17 0.11 0.12 0.21 
A(H3N2) 0.09 0.11 0.07 0.11 0.09 0.11 0.08 0.13 0.10 0.15 0.11 0.14 0.11 0.10 0.10 0.15 
B 7.79 7.28 5.40 7.55 10.37 6.44 7.79 7.54 8.84 6.55 6.42 8.76 10.54 4.99 7.15 9.56 
Zanamivir 
A(H1N1)pdm09 0.11 0.16 --e 0.18 0.12 0.18 0.12 0.19 0.13 0.21 0.16 0.19 0.14 0.17 0.15 0.21 
A(H3N2) 0.15 0.23 -- 0.25 0.17 0.26 0.17 0.26 0.18 0.30 0.22 0.20 0.15 0.23 0.20 0.20 
B 0.76 1.08 -- 1.19 1.02 1.00 0.69 1.05 0.58 0.89 0.77 0.73 0.98 0.80 0.58 0.84 
Peramivir 
A(H1N1)pdm09 0.05 0.06 0.03 0.05 --f -- -- 0.07 0.04 0.07 0.05 0.06 0.05 0.06 0.06 0.08 
A(H3N2) 0.07 0.09 0.05 0.08 -- -- -- 0.10 0.07 0.12 0.08 0.09 0.07 0.08 0.07 0.09 
B 0.43 0.55 0.27 0.40 -- -- -- 0.39 0.35 0.48 0.35 0.35 0.46 0.41 0.37 0.44 
Abbreviations - CDPH: California Department of Public Health; USLPH: Utah Unified State Laboratories-Public Health; WSLH: Wisconsin State Laboratory of 
Hygiene; CDC: Centers for Disease Control and Prevention. 
a Includes 940 U.S. virus isolates tested by NSRC-Is, and 1827 tested by CDC. 
b Includes 2114 U.S. virus isolates tested by NSRC-Is, and 801 tested by CDC. 
c Includes 2757 U.S. virus isolates tested by NSRC-Is, and 924 tested by CDC. 
d Includes 2460 U.S. virus isolates tested by NSRC-Is, and 573 tested by CDC. 
e Zanamivir was not available for testing in WSLH during 2011-12. 
f Peramivir was not assessed by NSRC-Is during 2012-13. 
